Earth Science Tech Reports 57% Jump in Fiscal Q1 Net Income, Advances Strategic Growth

Earth Science Tech, Inc. (OTC: ETST) has reported a robust start to its fiscal year, posting a 57% increase in net income for the first quarter of 2027 compared to the same period last year. The company’s net income reached $715,697, driven by revenue of $9.0 million, a 3% rise from the prior-year period. Gross profit climbed to $6.3 million, while operating cash flow more than doubled to $707,131, underscoring the company’s strengthening financial position. Total assets also grew to $10.4 million, and diluted earnings per share improved to $0.003 from $0.001.

A notable highlight of the quarter was the company’s aggressive share repurchase program, during which it bought back and retired more than 3.7 million common shares without incurring additional debt. This move signals management’s confidence in the company’s valuation and its commitment to enhancing shareholder value. The company’s balance sheet remains solid, with no new debt added during the quarter.

Earth Science Tech operates as a diversified holding company focused on the health and wellness sector, building a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The company’s healthcare operations are supported by investments in real estate and asset management activities, as well as a consumer products business. The core of its value proposition lies in the seamless integration of patient care—from consultation to fulfillment—achieved through the synergy of its specialized subsidiaries.

During the quarter, all key operating subsidiaries remained profitable, and the company continued to expand the licensing footprint of its compounding pharmacy operations across the United States. Management is also evaluating opportunities to broaden its telehealth and pharmacy fulfillment platforms, which could position the company for further growth in the rapidly evolving digital health landscape.

Looking ahead, Earth Science Tech will hold its annual shareholder meeting on Aug. 31, 2026, where investors will vote on several key proposals, including the cancellation of the company’s Series B Preferred Stock. Management will also provide updates on a potential exchange uplisting aimed at improving liquidity and market visibility. Such a move could attract a broader base of institutional investors and enhance the company’s profile in the financial markets.

The company’s strategic initiatives come at a time when the healthcare industry is increasingly embracing integrated care models and digital solutions. By expanding its compounding pharmacy licensing and enhancing its telehealth capabilities, Earth Science Tech is positioning itself to capitalize on these trends. The potential uplisting to a major exchange could also provide the company with greater access to capital markets, enabling it to fund future expansion and innovation.

For investors, the strong quarterly results and strategic direction suggest that Earth Science Tech is on a solid growth trajectory. The company’s ability to generate positive cash flow and reduce share count while investing in expansion is a positive signal. As the company continues to execute its plan, stakeholders will be watching to see how these initiatives translate into sustained value creation.